Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747991 | 1.00 | BTK (0.48) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL21747910 | 0.95 | BTK (0.47) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL21747950 | 0.91 | BTK (0.38) | BTKFGFR4CREBBPALKCYP11B2 | |
| SCHEMBL21761347 | 0.90 | BTK (0.53) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL29700770 | 0.88 | BTK (0.47) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL21760365 | 0.88 | BTK (0.47) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL21747965 | 0.86 | ALK (0.37) | BTKFGFR4JAK3ALKCYP11B2 | |
| SCHEMBL21761353 | 0.85 | BTK (0.46) | BTKFGFR4JAK3CCNKCDK12 | |
| SCHEMBL21753139 | 0.85 | BRD4 (0.38) | BTKCREBBPALKCYP11B2BRD4 | |
| SCHEMBL29700787 | 0.85 | BRD4 (0.38) | BTKCREBBPALKCYP11B2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | BTK 148/4885FGFR4 18/4885JAK3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.